Synapse - Jonathan Rosenberg

Results (463)

Enfortumab vedotin with or without pembrolizumab in cisplatin-ineligible patients with previously untreated locally advanced or metastatic urothelial cancer

Journal Article

O'Donnell, P. H.; Milowsky, M. I.; Petrylak, D. P.; Hoimes, C. J.; Flaig, T. W.; Mar, N.; Moon, H. H.; Friedlander, T. W.; McKay, R. R.; Bilen, M. A.; more...
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save

MAIN-CAV: Phase III randomized trial of maintenance cabozantinib and avelumab versus avelumab after first-line platinum-based chemotherapy in patients (pts) with metastatic urothelial cancer (mUC; Alliance A032001)

Meeting Abstract

Gupta, S.; Ballman, K. V.; Galsky, M. D.; Morris, M. J.; Sridhar, S. S.; Chen, R. C.; Chan, T. A.; Wen, Y.; Grivas, P.; Tan, A.; more...
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save

An in-progress phase 2 window of opportunity (WOO) trial of targeted therapy with erdafitinib for patients with recurrent FGFR3-altered non–muscle-invasive bladder cancer (NMIBC)

Meeting Abstract

Dsouza, N.; Gaffney, C.; Hernandez, C.; Moran, P.; Worth, K.; McCarter, M.; de Jesus, M. R.; Solit, D. B.; Sarungbam, J.; Al-Ahmadie, H. A.; more...
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save

Big data in oncology: Challenges and solutions

Meeting Abstract

Shah, N. J.; Bahadur, N.; Niederhausern, A.; Insinga, A.; Shah, I.; West, G.; Ahmad, H.; Martin, S.; Watson, A.; Nichols, C.; more...
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save

Associations of diet with survival of patients (pts) with metastatic cancer of the urothelium (mUC) and renal cell carcinoma (mRCC) on immune checkpoint blockade (ICB)

Meeting Abstract

Guercio, B. J.; Ratna, N.; Gavrilov, D.; Duzgol, C.; Akhlaq, M.; Teo, M. Y.; Regazzi, A. M.; Kotecha, R. R.; Funt, S. A.; Aggen, D. H.; more...
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save

Study EV-103: Neoadjuvant treatment with enfortumab vedotin monotherapy in cisplatin-ineligible patients (pts) with muscle invasive bladder cancer (MIBC): Updated results for Cohort H

Meeting Abstract

Flaig, T. W.; Rosenberg, J. E.; Hoimes, C. J.; O'Donnell, P. H.; Mar, N.; Gourdin, T. S.; Henry, S.; Bilen, M. A.; George, S.; Barata, P. C.; more...
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save

Enfortumab vedotin (EV) with or without pembrolizumab (P) in patients (pts) who are cisplatin-ineligible with previously untreated locally advanced or metastatic urothelial cancer (la/mUC): Additional 3-month follow-up on cohort K data

Meeting Abstract

Friedlander, T. W.; Milowsky, M. I.; O'Donnell, P. H.; Petrylak, D. P.; Hoimes, C. J.; Flaig, T. W.; Mar, N.; Moon, H. H.; McKay, R. R.; Bilen, M. A.; more...
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save

Long-term outcomes of pembrolizumab (pembro) in combination with gemcitabine (gem) and concurrent hypofractionated radiation therapy (RT) as bladder sparing treatment for muscle-invasive urothelial cancer of the bladder (MIUC): A multicenter phase 2 trial

Meeting Abstract

Economides, M. P.; Milowsky, M. I.; O'Donnell, P. H.; Alva, A. S.; Kollmeier, M.; Rose, T. L.; Pitroda, S. P.; Rosenberg, J. E.; Hochman, T.; Goldberg, J. D.; more...
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save

Study EV-103 dose escalation/cohort A: Long-term outcome of enfortumab vedotin + pembrolizumab in first-line (1L) cisplatin-ineligible locally advanced or metastatic urothelial carcinoma (la/mUC) with nearly 4 years of follow-up